# US 2008/0306127 A9 · Compounds and methods for inhibiting the interaction of BCL proteins with binding partners

> Agents: this data is available as JSON from the patentgrep API and MCP server — see https://patentgrep.com/llms.txt

- Number: US 2008/0306127 A9
- Document ID: US20080306127A9
- Status: Published application
- Kind: A9
- Application number: 11/600,332
- Filed: 2006-11-15
- Published: 2008-12-11
- Earliest claimed: 2004-06-17
- Assignees: Infinity Pharmaceuticals, Inc.
- Inventors: Alfredo Castro; Edward Holson; Brian Hopkins; Nii Koney; Daniel Snyder; Thomas Tibbitts
- Web page: https://patentgrep.com/patent/US20080306127A9

## CPC

- C07D 261/02: not condensed with other rings
- A61P 35/00: Antineoplastic agents
- A61P 35/02: specific for leukemia
- A61P 35/04: specific for metastasis
- C07D 261/18: Carbon atoms having three bonds to hetero atoms, with at the most one bond to halogen
- C07D 413/10: linked by a carbon chain containing aromatic rings
- C07D 413/12: linked by a chain containing hetero atoms as chain links
- C07D 417/12: linked by a chain containing hetero atoms as chain links
- C07D 498/04: Ortho-condensed systems
- C07D: HETEROCYCLIC COMPOUNDS (macromolecular compounds C08)
- A61P: SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS

## Abstract

One aspect of the present invention relates to heterocyclic compounds that bind to bcl proteins and inhibit Bcl function. Another aspect of the present invention relates to compositions comprising a heterocyclic compound of the invention. The present invention provides methods for treating and modulating disorders associated with hyperproliferation, such as cancer.

## Claims

### Claim 1

A compound of formula 1:
or a pharmaceutically acceptable salt thereof;
wherein independently for each occurrence;
n is 0, 1, 2, 3, or 4;
R1 independently for each occurrence is H, alkyl, alkenyl, alkynyl, aryl, aralkyl, heterocyclyl, heterocyclylalkyl, heteroaryl, heteroaralky, halide, hydroxyl, alkoxyl, aryloxy, acyloxy, amino, alkylamino, arylamino, acylamino, aralkylamino, nitro, acylthio, carboxamide, carboxyl, nitrile, —COR5, —CO2R5, —N(R5)CO2R6, —OC(O)N(R5)(R6), —N(R5)SO2R6, or —N(R5)C(O)N(R5)(R6);
R2 and R3 independently for each occurrence are H, alkyl, alkenyl, alkynyl, aryl, aralkyl, heterocyclyl, heterocyclylalkyl, heteroaryl, heteroaralkyl, or —[C(R5)(R6)]p—R4; or has the formula 1a
wherein
m is 0, 1, 2, 3, 4, or 5;
R7 for each occurrence independently is H, alkyl, aryl, alkenyl, halide, hydroxyl, alkoxyl, alkenyloxy, aryloxy, acyloxy, amino, alkylamino, arylamino, acylamino, aralkylamino, nitro, acylthio, carboxamide, carboxyl, nitrile, —OSO3R5, —SO2R5, —S(O)R5, —SR5, —PO2OR5, —OPO2OR5, —COR5, —CO2R5, —OCH2CO2R5, or —OCH2C(O)N(R5)(R6); or two occurrences of R7 taken together may form a monocyclic ring between 5-8 ring atoms, of which, one, two, or three atoms are independently S, O, or N;
R4 is halide, hydroxyl, alkoxyl, aryloxy, acyloxy, amino, alkylamino, arylamino, acylamino, aralkylamino, nitro, acylthio, carboxamide, carboxyl, nitrile, —OSO3R5, —SO2R5, —S(O)R5, —PO2OR5, —OPO2OR5, —COR5, —CO2R5, —N(R5)CO2R6, —OC(O)N(R5)(R6), —N(R5)SO2R6, or —N(R5)C(O)N(R5)(R6); and
each of R5 and R6 independently for each occurrence is H, alkyl, alkenyl, alkynyl, aryl, aralkyl, cycloalkyl, heterocyclyl, heterocyclylalkyl, heteroaryl, or heteroaralkyl; or R5 and R6 taken together form a monocyclic ring with 4-8 ring atoms, of which one, two, or three ring atoms are independently S, O, or N.

### Claim 2

A compound selected from the group consisting of:

### Claim 3 (depends on 1, 2)

A pharmaceutical composition, comprising a compound of claim 1 or 2; and at least one pharmaceutically acceptable excipient.

### Claim 4 (depends on 1, 2)

A method of treating cancer, comprising the step of administering to a patient in need thereof a therapeutically effective amount of a compound of claim 1 or 2.

### Claim 5 (depends on 4)

The method of claim 4, wherein the cancer is follicular lymphoma, diffuse large B-cell lymphoma, mantle cell lymphoma, chronic lymphocytic leukemia prostrate cancer, breast cancer, neuroblastoma, colorectal, endometrial, ovarian, lung cancer, hepatocellular carcinoma, multiple myeloma, head and neck or testicular cancer.

### Claim 6 (depends on 4)

The method of claim 4, wherein the cancer over-expresses a Bcl protein.

### Claim 7 (depends on 4)

The method of claim 4, wherein the cancer is dependent upon a Bcl protein for growth and survival.

### Claim 8 (depends on 6, 7)

The method of claim 6 or 7, wherein said Bcl protein is Bcl-2.

### Claim 9 (depends on 6, 7)

The method of claim 6 or 7, wherein said Bcl protein is Bcl-xL.

### Claim 10 (depends on 4)

The method of claim 4, wherein the cancer exhibits a t(14;18) chromosomal translocation.

### Claim 11 (depends on 1, 2)

A method of treating a bcl-mediated disorder, comprising the step of:
administering to a patient in need thereof a therapeutically effective amount of a compound of claim 1 or 2.

### Claim 12 (depends on 11)

The method of claim 11, wherein the bcl-mediated disorder is cancer or neoplastic disease.

### Claim 13 (depends on 12)

The method of claim 12, wherein said cancer or neoplastic disease is selected from the group consisting of acute leukemia, acute lymphocytic leukemia, acute myelocytic leukemia, myeloblastic, promyelocytic, myelomonocytic, monocytic, erythroleukemia, chronic leukemia, chronic myelocytic (granulocytic) leukemia, chronic lymphocytic leukemia, polycythemia Vera, Hodgkin's disease, non-Hodgkin's disease; multiple myeloma, Waldenstrom's macroglobulinemia, heavy chain disease, fibrosarcoma, myxosarcoma, liposarcoma, chondrosarcoma, osteogenic sarcoma, chordoma, angiosarcoma, endotheliosarcoma, lymphangiosarcoma, lymphangioendotheliosarcoma, synovioma, mesothelioma, Ewing's tumor, leiomyosarcoma, rhabdomyosarcoma, colon carcinoma, pancreatic cancer, breast cancer, ovarian cancer, prostate cancer, squamous cell carcinoma, basal cell carcinoma, adenocarcinoma, sweat gland carcinoma, sebaceous gland carcinoma, papillary carcinoma, papillary adenocarcinomas, stadenocarcinoma, medullary carcinoma, bronchogenic carcinoma, renal cell carcinoma, hepatoma, bile duct carcinoma, choriocarcinoma, seminoma, embryonal carcinoma, Wilms' tumor, cervical cancer, uterine cancer, testicular tumor, lung carcinoma, small cell lung carcinoma, bladder carcinoma, epithelial carcinoma, glioma, astrocytoma, medulloblastoma, craniopharyngioma, ependymoma, pinealoma, hemangioblastoma, acoustic neuroma, oligodendroglioma, meningioma, melanoma, neuroblastoma, retinoblastoma, and endometrial cancer.

### Claim 14 (depends on 1, 2)

A method of treating a bcl-mediated disorder, comprising the step of:
co-administering to a patient in need thereof a therapeutically effective amount of a chemotherapeutic agent; and a therapeutically effective amount of a compound of claim 1 or 2.

### Claim 15 (depends on 14)

The method of claim 14, wherein the bcl-mediated disorder is cancer or neoplastic disease.

### Claim 16 (depends on 15)

The method of claim 15, wherein said cancer or neoplastic disease is selected from the group consisting of acute leukemia, acute lymphocytic leukemia, acute myelocytic leukemia, myeloblastic, promyelocytic, myelomonocytic, monocytic, erythroleukemia, chronic leukemia, chronic myelocytic (granulocytic) leukemia, chronic lymphocytic leukemia, polycythemia Vera, Hodgkin's disease, non-Hodgkin's disease; multiple myeloma, Waldenstrom's macroglobulinemia, heavy chain disease, fibrosarcoma, myxosarcoma, liposarcoma, chondrosarcoma, osteogenic sarcoma, chordoma, angiosarcoma, endotheliosarcoma, lymphangiosarcoma, lymphangioendotheliosarcoma, synovioma, mesothelioma, Ewing's tumor, leiomyosarcoma, rhabdomyosarcoma, colon carcinoma, pancreatic cancer, breast cancer, ovarian cancer, prostate cancer, squamous cell carcinoma, basal cell carcinoma, adenocarcinoma, sweat gland carcinoma, sebaceous gland carcinoma, papillary carcinoma, papillary adenocarcinomas, stadenocarcinoma, medullary carcinoma, bronchogenic carcinoma, renal cell carcinoma, hepatoma, bile duct carcinoma, choriocarcinoma, seminoma, embryonal carcinoma, Wilms' tumor, cervical cancer, uterine cancer, testicular tumor, lung carcinoma, small cell lung carcinoma, bladder carcinoma, epithelial carcinoma, glioma, astrocytoma, medulloblastoma, craniopharyngioma, ependymoma, pinealoma, hemangioblastoma, acoustic neuroma, oligodendroglioma, meningioma, melanoma, neuroblastoma, retinoblastoma, and endometrial cancer.

### Claim 17 (depends on 14)

The method of claim 14, wherein the bcl-mediated disorder over-expresses a Bcl protein.

### Claim 18 (depends on 14)

The method of claim 14, wherein the bcl-mediated disorder is dependent upon Bcl protein for growth and survival.

### Claim 19 (depends on 17, 18)

The method of claim 17 or 18, wherein said Bcl protein is Bcl-2.

### Claim 20 (depends on 17, 18)

The method of claim 17 or 18, wherein said Bcl protein is Bcl-xL.

### Claim 21 (depends on 14)

The method of claim 14, wherein the bcl-mediated disorder exhibits a t(14;18) chromosomal translocation.

### Claim 22 (depends on 4, 11)

The method of claim 4, 11, or 14, wherein said compound or compounds are administered parenterally.

### Claim 23 (depends on 4, 11)

The method of claim 4, 11, or 14, wherein said compound or compounds are administered intramuscularly, intravenously, subcutaneously, orally, topically or intranasally.

### Claim 24 (depends on 4, 11)

The method of claim 4, 11, or 14, wherein said compound or compounds are administered systemically.

### Claim 25 (depends on 4, 11)

The method of claim 4, 11, or 14, wherein said patient is a mammal.

### Claim 26 (depends on 4, 11)

The method of claim 4, 11, or 14, wherein said patient is a primate.

### Claim 27 (depends on 4, 11)

The method of claim 4, 11, or 14, wherein said patient is a human.
